Senti Biosciences Has Received A Notice Of Allowance For Its U.S. Patent Application 17/338,528 Titled "Chimeric Receptors And Methods Of Use Thereof (For Treatment Of Acute Myeloid Leukemia)"
Portfolio Pulse from Benzinga Newsdesk
Senti Biosciences has received a Notice of Allowance for its U.S. patent application 17/338,528 titled 'Chimeric Receptors and Methods of Use Thereof' for the treatment of Acute Myeloid Leukemia.
October 03, 2023 | 5:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Senti Biosciences' patent approval could potentially lead to a new treatment for Acute Myeloid Leukemia, which may positively impact the company's stock.
The approval of a patent for a potential treatment for Acute Myeloid Leukemia could lead to increased revenues for Senti Biosciences if the treatment is successful and gets to market. This could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100